STOCK TITAN
  1. Home
  2. News
  3. GTHX

G1 Therapeutics Inc - GTHX STOCK NEWS

Welcome to our dedicated news page for G1 Therapeutics (Ticker: GTHX), a resource for investors and traders seeking the latest updates and insights on G1 Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect G1 Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of G1 Therapeutics's position in the market.

News
G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
G1 Therapeutics, Inc. (Nasdaq: GTHX) to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
conferences
-
News
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
G1 Therapeutics, Inc. (Nasdaq: GTHX) announced the grant of inducement stock options and restricted stock units to three new employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan. The stock options are exercisable at $3.11 per share, with a ten-year term and vesting over four years. The RSUs have a four-year term, with 25% vesting on the first anniversary of the grant date, and the remainder vesting semi-annually over the remaining three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
none
-
News
G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
Rhea-AI Summary
G1 Therapeutics, Inc. (Nasdaq: GTHX) announced that data from the randomized Phase 2 Metastatic Triple Negative Breast Cancer (mTNBC) Trial indicate that prior use of Trilaciclib with cytotoxic chemotherapy is highly correlated to improved long-term survival with subsequent anticancer therapies. Improved long-term survival was also observed in patients who received prior Trilaciclib with cytotoxic therapy and were unable to receive subsequent anticancer therapy. The data were presented at the 2023 San Antonio Breast Cancer Symposium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
none
News
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
G1 Therapeutics, Inc. (Nasdaq: GTHX) announced the grant of inducement stock options and restricted stock units to a new employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan. The stock options are exercisable at $2.00 per share, with a ten-year term and vesting over four years, while the RSUs have a four-year term and vesting over the same period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
Rhea-AI Summary
G1 Therapeutics, Inc. (Nasdaq: GTHX) announced that an abstract exploring the long-term impact of trilaciclib on survival outcomes in patients with metastatic triple negative breast cancer (mTNBC) from the Company’s Phase 2 trial (NCT02978716) will be presented at the 2023 San Antonio Breast Cancer Symposium. Results indicate improved long-term survival benefits for patients who received trilaciclib prior to cytotoxic chemotherapy, leading to substantially longer survival than patients who had previously received chemotherapy alone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.59%
Tags
conferences
-
News
G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights
Rhea-AI Summary
G1 Therapeutics, Inc. reported total revenue of $12.3 million for Q3 2023, including $10.8 million in net COSELA revenue. Vial volume grew 3% over the previous quarter. The company confirmed the expectation of an interim overall survival analysis for the Phase 3 PRESERVE 2 trial in metastatic triple-negative breast cancer (TNBC) in Q1 2024. G1 also reiterated the expectation of initial overall survival results from a Phase 2 trial of trilaciclib in combination with an antibody-drug conjugate (ADC) in Q1 2024. COSELA was recommended in the updated ASCO Small Cell Lung Cancer (SCLC) guidelines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.79%
Tags
earnings
News
Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Rhea-AI Summary
G1 Therapeutics presents new real-world evidence at ASCO Quality Care Symposium indicating that trilaciclib administered prior to chemotherapy in patients with ES-SCLC lowers hospitalization rates and cytopenia events and may improve survival. Multiple analyses also highlight the impact of chemotherapy-induced myelosuppression on healthcare resource utilization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.83%
Tags
none
-
News
G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)
Rhea-AI Summary
G1 Therapeutics' COSELA recommended as a myeloid supportive agent in updated ASCO SCLC guidelines
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.88%
Tags
none
-
News
G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023
Rhea-AI Summary
G1 Therapeutics to provide financial and corporate update for Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.88%
Tags
earnings
News
G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
G1 Therapeutics to present at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Stock GTHX logo
G1 Therapeutics Inc

Nasdaq:GTHX

GTHX Rankings

#3738 Ranked by Market Cap
#5408 Ranked by Stock Gains
N/A Ranked by Dividends

GTHX Stock Data

237.51M
43.59M
11.68%
30.15%
5.28%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Research Triangle Park

About GTHX

g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.